SCHEMBL10062372

SCHEMBL10062372

O=C(NNc1c2ccccc2nc2ccccc12)c1ccccn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 1.00
GAA P10253 13/20 0.62
KMT2A Q03164 12/20 0.62
MEN1 O00255 11/20 0.62
MMP14 P50281 3/20 0.62
MAPT P10636 11/20 0.61
POLB P06746 8/20 0.61
LMNA P02545 7/20 0.61
MAPK1 P28482 6/20 0.61
L3MBTL1 Q9Y468 4/20 0.61
HTT P42858 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
KDM4E B2RXH2 8/20 0.59
GFER P55789 4/20 0.59
RECQL P46063 2/20 0.59
TDP1 Q9NUW8 4/20 0.58
NPSR1 Q6W5P4 3/20 0.58
ALDH1A1 P00352 2/20 0.58
USP2 O75604 1/20 0.58
MCL1 Q07820 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10062331 0.84 KDM5A (0.72) KDM5AMAPTLMNAL3MBTL1HTT
SCHEMBL10062380 0.83 KDM5A (0.70) KDM5AGAAMAPTHTTTDP1
SCHEMBL28871817 0.78 KDM5A (0.63) KDM5AKMT2AMAPTLMNAL3MBTL1
SCHEMBL10061980 0.78 KDM5A (0.63) KDM5AKMT2AMEN1MAPTPOLB
SCHEMBL10061972 0.78 GAA (0.76) KDM5AGAAKMT2AMEN1MMP14
SCHEMBL1147702 0.77 KDM4E (0.73) KDM5AMAPTLMNAL3MBTL1HTT
SCHEMBL28225518 0.77 KDM5A (0.62) KDM5AKMT2AMAPTPOLBLMNA
SCHEMBL4411512 0.75 KDM5A (0.60) KDM5AGAAMAPTLMNAHTT
SCHEMBL23388826 0.74 SMN1; SMN2 (0.61) KDM5AGAAMAPTLMNAL3MBTL1
SCHEMBL29995352 0.74 SMN1; SMN2 (0.61) KDM5AGAAMAPTLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1853920-B1 FLUORESCENCE POLARIZATION ASSAYS FOR ACETYLTRANSFERASE/DEACETYLASE ACTIVITY SIRTRIS PHARMACEUTICALS INC (US) 2012-02-01 EP disclosed
US-20100168084-A1 Therapeutic compounds and related methods of use ELIXIR PHARMACEUTICALS, INC. 2010-07-01 US disclosed
US-20100168084-A1 Therapeutic compounds and related methods of use ELIXIR PHARMACEUTICALS, INC. 2010-07-01 US disclosed
US-20090069301-A1 Acridine and Quinoline Derivatives as Sirtuin Modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2009-03-12 US disclosed
US-20090069301-A1 Acridine and Quinoline Derivatives as Sirtuin Modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2009-03-12 US disclosed
US-20080293081-A1 Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity SIRTRIS PHARMACEUTICALS, INC. (US) 2008-11-27 US disclosed
US-20080293081-A1 Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity SIRTRIS PHARMACEUTICALS, INC. (US) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168084-A1 Therapeutic compounds and related methods of use EP300, KAT2A, KAT6B KDM5A 971/4885GAA 119/4885KMT2A 422/4885
US-20090069301-A1 Acridine and Quinoline Derivatives as Sirtuin Modulators SIRT1, SIRT3, SIRT2 KDM5A 1060/4885GAA 220/4885KMT2A 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.